Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

ARA-290 Pre-Mixed 2mg Peptide

£10.91£37.91

ARA-290 is being studied as a possible wound-healing stimulant, an immune-modulator, and potential systemic lupus erythematosus (lupus or SLE) treatment,

Pre Mixed Cartridge and Kit:

  • 1 x Cartridge (The cartridge is premixed with the peptide vial of your choice and Bacteriostatic Water)
  • 1 x Peptide Cartridge Pen
  • 1 x Pen Carry Case
  • 3 x Pen Needle Tips

Single Mixed Cartridges (1,2 & 3) Come with:

  • 1,2 or 3 x Cartridge (The cartridge is premixed with the peptide vial of your choice and Bacteriostatic Water)
  • 3 x Pen Needle Tips

The single 1,2 & 3 cartridges do not come with a kit. Save 10% when buying 3 cartridges.

Buy 10 and get 10% Discount

481 in stock

Description

ARA-290 Pre-Mixed Peptide 2mg United States

This product is intended for research purposes only. To be used by trained professionals only.

ARA-290 is a non-erythropoietic peptide produced from erythropoietin that has showed promise in the treatment of a variety of diseases. The innate repair receptor, which is a heteromer comprising the erythropoietin receptor and the -common receptor, is activated by ARA-290. ARA-290 pre-mixed peptide has been shown in trials to stimulate tissue repair and regeneration, reduce inflammation, and improve overall health and wellness by activating this receptor.

The treatment of neuropathic pain is one of the most well-studied applications of ARA-290 pre-mixed peptide. Several studies have demonstrated that ARA-290 can give long-term pain relief with few adverse effects. ARA-290 may function by regulating spinal microglia, decreasing inflammation, and facilitating tissue repair in afflicted areas [1].

In addition, ARA-290 has shown potential in the treatment of type 2 diabetes. According to one study, ARA-290 improved metabolic management and neuropathic symptoms in type 2 diabetic patients. This could be because the peptide improves blood flow and oxygenation to injured tissues while also promoting tissue repair and regeneration [2].

Other studies have looked into the possible benefits of ARA-290 in the treatment of sarcoidosis, autoimmune illnesses, and other diseases. ARA-290 has been proven to ameliorate small fibre neuropathy in sarcoidosis patients, reduce inflammation and tissue damage in experimental autoimmune neuritis, and protect against SLE (systemic lupus erythematosus) [3].


References:

[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3883966/

[2] https://www.researchgate.net/ publication/268230288_ARA_290_ a_Nonerythropoietic_ Peptide_ Engineered_from_Erythropoietin_ Improves_Metabolic_Control_ and_Neuropathic_Symptoms_in_ Patients_with_Type_2_Diabetes

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6010693/


Molecular Formula: C51H84N16O21
Sequence: XEQLERALNSS
Storage: Lyophilized peptides stored below -18°C.

ARA-290 HPLC 2023 Certificates_DIRECT PEPTIDES

 

 

 

 

 

 

 

 


ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our United States Direct Peptides website: https://united-states.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.


BUY ARA-290 Pre-Mixed Peptide ONLINE today From United States Direct Peptides

You may also like…